Insider Selling: DexCom (NASDAQ:DXCM) Director Sells 1,012 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

DexCom Stock Up 2.5%

DXCM stock traded up $1.48 during trading on Wednesday, reaching $59.61. 6,844,335 shares of the company traded hands, compared to its average volume of 4,567,267. The business has a 50 day simple moving average of $68.12 and a 200 day simple moving average of $77.39. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $23.25 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the prior year, the firm posted $0.45 earnings per share. The company’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on DXCM shares. Truist Financial restated a “buy” rating and set a $82.00 target price (down from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Stifel Nicolaus assumed coverage on shares of DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price objective on the stock. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $84.00 price objective on shares of DexCom in a research report on Monday, November 3rd. Mizuho lifted their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Finally, Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $87.62.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares in the last quarter. Jennison Associates LLC lifted its holdings in DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares in the last quarter. Geode Capital Management LLC boosted its stake in DexCom by 3.4% during the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock worth $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after buying an additional 1,868,241 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of DexCom in the first quarter worth about $554,893,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.